Suppr超能文献

度他雄胺,一种双重5α-还原酶抑制剂,可抑制雄激素作用并促进LNCaP前列腺癌细胞系中的细胞死亡。

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

作者信息

Lazier C B, Thomas L N, Douglas R C, Vessey J P, Rittmaster R S

机构信息

Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, NS, Canada.

出版信息

Prostate. 2004 Feb 1;58(2):130-44. doi: 10.1002/pros.10340.

Abstract

BACKGROUND

Reduction of T to DHT by 5alphaR in the prostate enhances androgenic activity for most targets. Inhibition of 5alphaR activity with finasteride attenuates androgen action in men and animal models. The objective of this study was to compare and contrast the effects of a potent new 5alphaR inhibitor, dutasteride, with finasteride in the LNCaP prostate cancer cell line.

METHODS

LNCaP cells were incubated for varying times with T or DHT in steroid-free medium in the absence or presence of increasing doses of dutasteride or finasteride and the effects on 5alphaR activity, PSA accumulation in the medium, and on cell proliferation were determined. Drug effects on apoptosis were investigated using Annexin V staining and a cell death ELISA assay. Effects of the drugs on AR ligand-binding activity and on AR protein levels were determined.

RESULTS

Dutasteride inhibited (3)H-T conversion to (3)H-DHT and, as anticipated, inhibited T-induced secretion of PSA and proliferation. However the drug also inhibited DHT-induced PSA secretion and cell proliferation (IC(50) approximately 1 microM). Finasteride also inhibited DHT action but was less potent than dutasteride. Dutasteride competed for binding the LNCaP cell AR with an IC(50) approximately 1.5 microM. High concentrations of dutasteride (10-50 microM), but not finasteride, in steroid-free medium, resulted in enhanced cell death, possibly by apoptosis. This was accompanied by loss of AR protein and decreased AR ligand-binding activity. Occupation of AR by R1881 partly protected against cell death and loss of AR protein. PC-3 prostate cancer cells, which do not contain AR, also were killed by high concentrations of dutasteride, as well as by 50 microM finasteride.

CONCLUSIONS

Dutasteride exhibited some inhibitory actions in LNCaP cells possibly related to 5alphaR inhibition but also had antiandrogenic effects at relatively low concentrations and cell death-promoting effects at higher concentrations. Finasteride also was antiandrogenic, but less than dutasteride. The antiandrogenic effects may be mediated by the mutant LNCaP cell AR. Promotion of cell death by dutasteride can be blocked, but only in part, by androgens.

摘要

背景

前列腺中5α还原酶将睾酮(T)转化为双氢睾酮(DHT)可增强大多数靶标的雄激素活性。非那雄胺抑制5α还原酶活性可减弱男性和动物模型中的雄激素作用。本研究的目的是在LNCaP前列腺癌细胞系中比较和对比一种新型强效5α还原酶抑制剂度他雄胺与非那雄胺的作用。

方法

在无类固醇培养基中,将LNCaP细胞与T或DHT孵育不同时间,同时加入递增剂量的度他雄胺或非那雄胺,测定其对5α还原酶活性、培养基中前列腺特异性抗原(PSA)积累以及细胞增殖的影响。使用膜联蛋白V染色和细胞死亡酶联免疫吸附测定法研究药物对细胞凋亡的影响。测定药物对雄激素受体(AR)配体结合活性和AR蛋白水平的影响。

结果

度他雄胺抑制(3)H-T向(3)H-DHT的转化,且如预期那样,抑制T诱导的PSA分泌和细胞增殖。然而,该药物也抑制DHT诱导的PSA分泌和细胞增殖(半数抑制浓度[IC(50)]约为1微摩尔)。非那雄胺也抑制DHT的作用,但效力低于度他雄胺。度他雄胺与LNCaP细胞AR结合的竞争IC(50)约为1.5微摩尔。在无类固醇培养基中,高浓度的度他雄胺(10 - 50微摩尔)而非非那雄胺可导致细胞死亡增加,可能是通过凋亡。这伴随着AR蛋白的丢失和AR配体结合活性的降低。R1881占据AR可部分防止细胞死亡和AR蛋白丢失。不含AR的PC - 3前列腺癌细胞也会被高浓度的度他雄胺以及50微摩尔的非那雄胺杀死。

结论

度他雄胺在LNCaP细胞中表现出一些可能与抑制5α还原酶相关的抑制作用,但在相对低浓度时也具有抗雄激素作用,在高浓度时具有促进细胞死亡的作用。非那雄胺也具有抗雄激素作用,但弱于度他雄胺。抗雄激素作用可能由突变的LNCaP细胞AR介导。度他雄胺促进细胞死亡的作用可被雄激素部分阻断,但仅为部分阻断。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验